Osimertinib Called "Home Run" for EGFR-Mutant NSCLC.

Adjuvant treatment with the tyrosine kinase inhibitor osimertinib will likely become a new standard of care in patients with EGFR-mutant non-small cell lung cancer. In the phase III ADAURA trial, 90% of patients with stage II-IIIA disease who received osimertinib were alive and free of cancer at 2 years, compared with 44% who received a placebo-results considered so striking that researchers unblinded the trial early. ©2020 American Association for Cancer Research.